课题基金 / 基金详情

Archer: Next-generation unstructured data access for hospitals and clinical trial sponsors, delivering efficiency, reducing costs and improving care

Archer: Next-generation unstructured data access for hospitals and clinical trial sponsors, delivering efficiency, reducing costs and improving care
Archer:为医院和临床试验申办者提供下一代非结构化数据访问,提高效率、降低成本并改善护理
批准号:
10096804
负责人:
金额:
$42.07万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
IgniteData是一家总部位于英国的创新型中小企业,其目标是通过其软件即服务平台 **Archer**,实现医疗保健提供商(电子健康记录(EHR))和临床试验申办者(电子数据采集(EDC))系统的互操作性。**项目目标/摘要 ** 第一代Archer已成功开发和部署,用于将结构化数据(例如EHR系统中的患者记录)从EHR传输到EDC。然而,** 高达85%的可操作健康数据以非结构化格式存储 **(例如病理学报告、放射学报告、术后记录中的临床叙述文本)。该项目将通过开发AI/NLP驱动的模块来创建第二代Archer,该模块将回答来自非结构化EHR数据的试验相关问题,并将结果输入EDC。**市场机会/需求 ** EHR中以非结构化格式存储的有价值数据目前是资源密集型的,并且难以提取。手动数据传输和审查仍然很常见,尽管通常耗时,周转缓慢且容易出错,因为可能会错过医疗条件和支持证据[Wong,2016]。源文件验证(手动数据传输所需,以避免错误)可单独占10-15%的试验成本(例如,约£1- 1.5 m/PII试验)。**影响/项目产出 * 直接从EHR中提取非结构化信息将大大降低目前与现场监控/审计相关的成本。*第二代Archer平台将在发布后的5年内实现转型性增长。
英文摘要
IgniteData is an innovative, UK-based SME with a goal to transform the interoperability of healthcare provider (Electronic Health Record (EHR)) and clinical trial sponsor (Electronic Data Capture (EDC)) systems through its Software-as-a-Service platform **Archer**.**Project Objectives/Summary**The first generation of Archer has been successfully developed and deployed to transfer structured data (e.g. patient records in EHR systems) from an EHR to an EDC. However, **up to 85% of actionable health data is stored in unstructured formats** (e.g. clinical narrative text found in Pathology reports, Radiology reports, Postoperative notes).This project will create the second-generation of Archer through the development of an AI-/NLP-driven module which answers trial-relevant questions from unstructured EHR data and inputs results into EDCs.**Market Opportunity/Need**The valuable data stored in unstructured formats within EHRs is currently resource-intensive and challenging to extract. Manual data transfer and reviews are still commonplace, despite being often time-consuming, slow-to-turnaround and error-prone since medical conditions and supporting evidence can potentially be missed \[Wong, 2016\]. Source-Document-Verification (required by manual data transfer to avoid errors) can alone account for 10-15% trial costs (e.g. ~£1-1.5m/PII trial).**Impacts/Project Outputs*** Directly extracting unstructured information from EHRs will enable exceptional reductions in the costs currently associated with on-site monitoring/auditing.* Second-generation Archer platform will deliver transformative growth within 5-years of launch.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Next Generation Majorana Nanowire Hybrids